Drug intelligence / Profile preview

V-212

Development stage: Phase 1
Lead developer: Virometix
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

V-212 is a synthetic, peptide-based vaccine developed by Virometix AG. It is designed to prevent pneumococcal disease, which is any type of illness caused by infection with the bacterium *Streptococcus pneumoniae*. The drug is currently in an ongoing Phase 1 clinical trial to evaluate its safety and immunogenicity in healthy adult volunteers. Virometix raised $15 million in a financing round to accelerate V-212's clinical development, including preparations for a Phase 1b combination trial.

Targets

Conserved Streptococcus pneumoniae surface protein epitopes

Beyond the preview

Go deeper on V-212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-212.

Explore the full profile